AstraZeneca Scored A 'Home Run' With Its Cancer Drug — And Shares Popped
AstraZeneca's lung cancer treatment, Tagrisso, hit a "home run amid high expectations," an analyst said Friday as AZN stock popped. Researchers tested Tagrisso use following surgery.